A German manufacturer and a Canadian drug developer are partnering to address the supply crunch of radioisotopes used in cancer treatments.
Isotope Technologies Munich (ITM) and British Columbia’s Alpha-9 Oncology have entered a global supply agreement for the development of Alpha-9's radiopharmaceutical therapies used to treat cancer.
The agreement includes the supply of Lutetium-177 for the development of Alpha-9's radiopharmaceutical candidates, which consist of Lutetium-177 combined with undisclosed targeting molecules. ITM will supply its medical radioisotope—specifically non-carrier-added Lutetium-177—to support Alpha-9's upcoming clinical trials and new drug development.
"Entering this strategic collaboration with Alpha-9 underscores our belief in the value of developing established beta-emitters such as Lutetium-177, to advance the radiopharmaceutical industry and maximize patient benefit," Steffen Schuster, CEO of ITM said in an announcement. "Our position as the world's largest supplier of n.c.a. Lutetium-177 [makes] us an ideal partner for Alpha-9. We look forward to working with a company that shares our vision of improving cancer care and outcomes for patients globally."
ITM holds a Drug Master File with the U.S. Food and Drug Administration for the manufacture and marketing of Lutetium-177.
Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.